File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions

TitleA pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions
Authors
Issue Date2009
PublisherAmerican Association for Cancer Research. The Journal's web site is located at http://cancerpreventionresearch.aacrjournals.org/
Citation
Cancer Prevention Research, 2009, v. 2 n. 10, p. 868-878 How to Cite?
AbstractQuadrivalent human papillomavirus (HPV) vaccine has been shown to provide protection from HPV 6/11/16/18-related cervical, vaginal, and vulvar disease through 3 years. We provide an update on the efficacy of the quadrivalent HPV vaccine against high-grade cervical, vaginal, and vulvar lesions based on end-of-study data from three clinical trials. Additionally, we stratify vaccine efficacy by several baseline characteristics, including age, smoking status, and Papanicolaou (Pap) test results. A total of 18,174 females ages 16 to 26 years were randomized and allocated into one of three clinical trials (protocols 007, 013, and 015). Vaccine or placebo was given at baseline, month 2, and month 6. Pap testing was conducted at regular intervals. Cervical and anogenital swabs were collected for HPV DNA testing. Examination for the presence of vulvar and vaginal lesions was also done. Endpoints included high-grade cervical, vulvar, or vaginal lesions (CIN 2/3, VIN 2/3, or ValN 2/3). Mean follow-up time was 42 months post dose 1. Vaccine efficacy against HPV 6/11/16/18-related high-grade cervical lesions in the per-protocol and intention-to-treat populations was 98.2% [95% confidence interval (95% CI), 93.3-99.8] and 51.5% (95% CI, 40.6-60.6), respectively. Vaccine efficacy against HPV 6/11/16/18-related high-grade vulvar and vaginal lesions in the per-protocol and intention-to-treat populations was 100.0% (95% CI, 82.6-100.0) and 79.0% (95% CI, 56.4-91.0), respectively. Efficacy in the intention-to-treat population tended to be lower in older women, women with more partners, and women with abnormal Pap test results. The efficacy of quadrivalent HPV vaccine against high-grade cervical and external anogenital neoplasia remains high through 42 months post vaccination. ©2009 American Association for Cancer Research.
Persistent Identifierhttp://hdl.handle.net/10722/125636
ISSN
2015 Impact Factor: 3.887
2015 SCImago Journal Rankings: 2.374
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorKjaer, SKen_HK
dc.contributor.authorSigurdsson, Ken_HK
dc.contributor.authorIversen, OEen_HK
dc.contributor.authorHernandezAvila, Men_HK
dc.contributor.authorWheeler, CMen_HK
dc.contributor.authorPerez, Gen_HK
dc.contributor.authorBrown, DRen_HK
dc.contributor.authorKoutsky, LAen_HK
dc.contributor.authorEng, HTen_HK
dc.contributor.authorGarcía, Pen_HK
dc.contributor.authorAult, KAen_HK
dc.contributor.authorGarland, SMen_HK
dc.contributor.authorLeodolter, Sen_HK
dc.contributor.authorOlsson, SEen_HK
dc.contributor.authorTang, GWKen_HK
dc.contributor.authorFerris, DGen_HK
dc.contributor.authorPaavonen, Jen_HK
dc.contributor.authorLehtinen, Men_HK
dc.contributor.authorSteben, Men_HK
dc.contributor.authorBosch, FXen_HK
dc.contributor.authorDillner, Jen_HK
dc.contributor.authorJoura, EAen_HK
dc.contributor.authorMajewski, Sen_HK
dc.contributor.authorMuñoz, Nen_HK
dc.contributor.authorMyers, ERen_HK
dc.contributor.authorVilla, LLen_HK
dc.contributor.authorTaddeo, FJen_HK
dc.contributor.authorRoberts, Cen_HK
dc.contributor.authorTadesse, Aen_HK
dc.contributor.authorBryan, Jen_HK
dc.contributor.authorMaansson, Ren_HK
dc.contributor.authorLu, Sen_HK
dc.contributor.authorVuocolo, Sen_HK
dc.contributor.authorHesley, TMen_HK
dc.contributor.authorSaah, Aen_HK
dc.contributor.authorBarr, Een_HK
dc.contributor.authorHaupt, RMen_HK
dc.date.accessioned2010-10-31T11:42:53Z-
dc.date.available2010-10-31T11:42:53Z-
dc.date.issued2009en_HK
dc.identifier.citationCancer Prevention Research, 2009, v. 2 n. 10, p. 868-878en_HK
dc.identifier.issn1940-6207en_HK
dc.identifier.urihttp://hdl.handle.net/10722/125636-
dc.description.abstractQuadrivalent human papillomavirus (HPV) vaccine has been shown to provide protection from HPV 6/11/16/18-related cervical, vaginal, and vulvar disease through 3 years. We provide an update on the efficacy of the quadrivalent HPV vaccine against high-grade cervical, vaginal, and vulvar lesions based on end-of-study data from three clinical trials. Additionally, we stratify vaccine efficacy by several baseline characteristics, including age, smoking status, and Papanicolaou (Pap) test results. A total of 18,174 females ages 16 to 26 years were randomized and allocated into one of three clinical trials (protocols 007, 013, and 015). Vaccine or placebo was given at baseline, month 2, and month 6. Pap testing was conducted at regular intervals. Cervical and anogenital swabs were collected for HPV DNA testing. Examination for the presence of vulvar and vaginal lesions was also done. Endpoints included high-grade cervical, vulvar, or vaginal lesions (CIN 2/3, VIN 2/3, or ValN 2/3). Mean follow-up time was 42 months post dose 1. Vaccine efficacy against HPV 6/11/16/18-related high-grade cervical lesions in the per-protocol and intention-to-treat populations was 98.2% [95% confidence interval (95% CI), 93.3-99.8] and 51.5% (95% CI, 40.6-60.6), respectively. Vaccine efficacy against HPV 6/11/16/18-related high-grade vulvar and vaginal lesions in the per-protocol and intention-to-treat populations was 100.0% (95% CI, 82.6-100.0) and 79.0% (95% CI, 56.4-91.0), respectively. Efficacy in the intention-to-treat population tended to be lower in older women, women with more partners, and women with abnormal Pap test results. The efficacy of quadrivalent HPV vaccine against high-grade cervical and external anogenital neoplasia remains high through 42 months post vaccination. ©2009 American Association for Cancer Research.en_HK
dc.languageengen_HK
dc.publisherAmerican Association for Cancer Research. The Journal's web site is located at http://cancerpreventionresearch.aacrjournals.org/en_HK
dc.relation.ispartofCancer Prevention Researchen_HK
dc.subject.meshCancer Vaccines - therapeutic use-
dc.subject.meshCervical Intraepithelial Neoplasia - prevention and control - virology-
dc.subject.meshGenital Diseases, Female - prevention and control - virology-
dc.subject.meshPapillomavirus Vaccines - therapeutic use-
dc.subject.meshUterine Cervical Neoplasms - prevention and control - virology-
dc.titleA pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesionsen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1940-6207&volume=2&issue=10&spage=868&epage=878&date=2009&atitle=A+pooled+analysis+of+continued+prophylactic+efficacy+of+quadrivalent+human+papillomavirus+(Types+6/11/16/18)+vaccine+against+high-grade+cervical+and+external+genital+lesions-
dc.identifier.emailTang, GWK:gwktang@hkucc.hku.hken_HK
dc.identifier.authorityTang, GWK=rp00328en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1158/1940-6207.CAPR-09-0031en_HK
dc.identifier.pmid19789295-
dc.identifier.scopuseid_2-s2.0-70449338341en_HK
dc.identifier.hkuros172079en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-70449338341&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume2en_HK
dc.identifier.issue10en_HK
dc.identifier.spage868en_HK
dc.identifier.epage878en_HK
dc.identifier.isiWOS:000270819300005-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridKjaer, SK=7004418213en_HK
dc.identifier.scopusauthoridSigurdsson, K=35475355400en_HK
dc.identifier.scopusauthoridIversen, OE=7102966661en_HK
dc.identifier.scopusauthoridHernandezAvila, M=7005968193en_HK
dc.identifier.scopusauthoridWheeler, CM=7202505711en_HK
dc.identifier.scopusauthoridPerez, G=16307983600en_HK
dc.identifier.scopusauthoridBrown, DR=7407095050en_HK
dc.identifier.scopusauthoridKoutsky, LA=7006120337en_HK
dc.identifier.scopusauthoridEng, HT=16306953500en_HK
dc.identifier.scopusauthoridGarcía, P=7201693727en_HK
dc.identifier.scopusauthoridAult, KA=7005241226en_HK
dc.identifier.scopusauthoridGarland, SM=7102220459en_HK
dc.identifier.scopusauthoridLeodolter, S=7005056838en_HK
dc.identifier.scopusauthoridOlsson, SE=7202623557en_HK
dc.identifier.scopusauthoridTang, GWK=7401633864en_HK
dc.identifier.scopusauthoridFerris, DG=17634377600en_HK
dc.identifier.scopusauthoridPaavonen, J=7102724434en_HK
dc.identifier.scopusauthoridLehtinen, M=35479268300en_HK
dc.identifier.scopusauthoridSteben, M=6602790643en_HK
dc.identifier.scopusauthoridBosch, FX=7201833375en_HK
dc.identifier.scopusauthoridDillner, J=7007135194en_HK
dc.identifier.scopusauthoridJoura, EA=7004817276en_HK
dc.identifier.scopusauthoridMajewski, S=7103224726en_HK
dc.identifier.scopusauthoridMuñoz, N=7102360543en_HK
dc.identifier.scopusauthoridMyers, ER=35433205900en_HK
dc.identifier.scopusauthoridVilla, LL=7102824355en_HK
dc.identifier.scopusauthoridTaddeo, FJ=6603004214en_HK
dc.identifier.scopusauthoridRoberts, C=35474924800en_HK
dc.identifier.scopusauthoridTadesse, A=6602812727en_HK
dc.identifier.scopusauthoridBryan, J=7202481712en_HK
dc.identifier.scopusauthoridMaansson, R=35146242700en_HK
dc.identifier.scopusauthoridLu, S=54899768500en_HK
dc.identifier.scopusauthoridVuocolo, S=16403558200en_HK
dc.identifier.scopusauthoridHesley, TM=6603486789en_HK
dc.identifier.scopusauthoridSaah, A=7006464069en_HK
dc.identifier.scopusauthoridBarr, E=7005643832en_HK
dc.identifier.scopusauthoridHaupt, RM=11940557600en_HK
dc.identifier.citeulike5909057-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats